DNLI in the 13F filings
Denali Therapeutics Inc · CUSIP 24823R105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 23 Jan 2026
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 5 listed it in both
- Shares listed
- 39,828,808
- combined, among listed positions
- Reported value
- $658m
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 15 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,200,718.
Managers listing DNLI in Q4 2025
28 of 28 holders
Largest increases and reductions, by shares
Increases
- ExodusPoint Capital Management LPnew position · 1,023,253 shares now+1,023,253
- Baillie Gifford & Coexisting position · 12,310,889 shares now+719,304
- Two Sigma Investments LPexisting position · 430,177 shares now+163,885
- Hudson Bay Capital Management LPexisting position · 450,000 shares now+145,000
- Citadel Advisors LLCexisting position · 779,148 shares now+90,924
Reductions
- Capital Research Global Investorsexisting position · 3,729,244 shares now-1,031,614
- Millennium Management LLCexisting position · 369,767 shares now-937,404
- Point72 Asset Management LPexisting position · 1,700,000 shares now-819,535
- T. Rowe Price Associates Incexisting position · 3,915,951 shares now-652,417
- Voloridge Investment Management LLCexisting position · 591,461 shares now-344,769
New positions and exits
New (5)
Exited (3)
- Schonfeld Strategic Advisors LLCwas $3.3m
- Squarepoint Ops LLCwas $1.2m
- Verition Fund Management LLCwas $256k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2017 | 2 | $78m | n.a. | n.a. |
| Q1 2018 | 1 | $102m | n.a. | n.a. |
| Q2 2018 | 1 | $82m | n.a. | n.a. |
| Q3 2018 | 2 | $122m | n.a. | n.a. |
| Q4 2018 | 2 | $131m | n.a. | n.a. |
| Q1 2019 | 2 | $146m | n.a. | n.a. |
| Q2 2019 | 2 | $154m | n.a. | n.a. |
| Q3 2019 | 2 | $113m | n.a. | n.a. |
| Q4 2019 | 2 | $133m | n.a. | n.a. |
| Q1 2020 | 3 | $165m | n.a. | n.a. |
| Q2 2020 | 2 | $226m | n.a. | n.a. |
| Q3 2020 | 4 | $406m | n.a. | n.a. |
| Q4 2020 | 7 | $1.6bn | n.a. | n.a. |
| Q1 2021 | 7 | $1.2bn | n.a. | n.a. |
| Q2 2021 | 5 | $1.7bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.1bn | n.a. | n.a. |
| Q4 2021 | 4 | $709m | n.a. | n.a. |
| Q1 2022 | 3 | $507m | n.a. | n.a. |
| Q2 2022 | 5 | $481m | n.a. | n.a. |
| Q3 2022 | 8 | $629m | n.a. | n.a. |
| Q4 2022 | 6 | $766m | n.a. | n.a. |
| Q1 2023 | 4 | $423m | n.a. | n.a. |
| Q2 2023 | 6 | $760m | n.a. | n.a. |
| Q3 2023 | 5 | $539m | n.a. | n.a. |
| Q4 2023 | 8 | $577m | 4 | 4 |
| Q1 2024 | 9 | $669m | 7 | 2 |
| Q2 2024 | 9 | $829m | 5 | 3 |
| Q3 2024 | 7 | $1.1bn | 4 | 4 |
| Q4 2024 | 6 | $625m | 1 | 5 |
| Q1 2025 | 5 | $422m | 2 | 3 |
| Q2 2025 | 4 | $270m | 2 | 3 |
| Q3 2025 | 5 | $333m | 4 | 1 |
| Q4 2025 | 6 | $342m | 15 | 15 |
| Q1 2026 | 7 | $372m | 13 | 16 |
| Q2 2026 | 5 | $514m | 13 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
DNLI and GILD →DNLI and AMGN →DNLI and ARGX →Choose a stock to compare with DNLI →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own DNLI, latest filings →Back to the 13F Explorer →